PsychiatricTimes Members: Login | Register

|     

PsychiatricTimes SearchMedica Medline Drugs

Powered by SearchMedica

 
Risk Assessment
News
Current Issues
Blogs
Special Reports
CME
Conferences
Resources
Careers
Multimedia
About Us
 

Home »

Psychiatric Times. Vol. 26 No. 5
Pages: 1  2  3  
Previous Next
Psychopharmacology 

Hypnotics

By Malcolm H. Lader, MD, PhD, LLB | May 11, 2009
Dr Lader is professor emeritus of clinical psychopharmacology at the Institute of Psychiatry, King’s College London. He has no known conflicts of interest concerning the contents of this article.

Zaleplon is also a selective compound with a very short half-life that averages only 1 hour. The drug shortens sleep onset without usually prolonging total sleep time. Residual effects are absent, and memory is minimally disturbed.

A meta-analysis of benzodiazepines and related drugs in the treatment of insomnia found definite efficacy with respect to prolonging total sleep duration by over an hour but only a nonsignificant reduction in sleep latency.10 Memory impairment was reported in several of the studies that were cited.

(MORE: Antidepressants: Brand Name or Generic?)

Another risk-to-benefit meta-analysis in the elderly concluded that the risks may outweigh the benefits.11 The newer compounds, including eszopiclone and ramelteon, may be more effective in the elderly and better tolerated than standard hypnotic benzodiazepines.12

Adverse effects
The most common adverse effects of the hypnotic benzodiazepines are tiredness, drowsiness, and torpor—all features of oversedation. The effects are dose- and time-related and are maximal within the first 2 hours after large doses. This presents a danger if the person with insomnia takes a dose of medication and then wakes up.13 Next-day drowsiness is most noticeable during the first week of treatment, after which it largely disappears, probably because of a true tolerance effect. Patients should be warned of the potential adverse effects of any prescribed benzodiazepine and the initial dosage should be considered carefully. Most benzodiazepines can cause problems, especially when given at higher doses and in the elderly.

Residual effects can be a problem, especially when long-acting drugs are used repeatedly. Dosage is important because as the dosage is increased, residual effects increase in both magnitude and duration. Remember that hypnotics are the only class of drugs in which the main therapeutic effect (drowsiness) is the same as the main unwanted effect; the 2 are merely separated by 8 hours. Psychomotor performance may be affected the next day, with elderly drivers at particularly high risk. In addition, potentiating effects of alcohol(Drug information on alcohol) can occur. Paradoxical behavioral responses (such as uncontrollable weeping; increased aggression and hostility; and acute rage reactions or uncharacteristic criminal behavior, such as shoplifting) can develop in patients taking a benzodiazepine.

Other unwanted effects include respiratory depression, excessive weight gain, rash, impaired sexual function, menstrual irregularities and, rarely, blood dyscrasias. The use of benzodiazepines in pregnancy is generally regarded as reasonably safe, but benzodiazepines pass into the fetus and can produce respiratory depression in the neonate. Benzodiazepines and related drugs cross over into the mother’s milk and can oversedate the baby. Breastfeeding should therefore be discouraged if benzodiazepines are prescribed, especially in high dosages.

Overdosing
Overdosing with benzodiazepines is common; death is not. By themselves, benzodiazepines are only hazardous to children and the physically frail, especially those with respiratory illness. Typically, the person falls into a deep sleep but can be roused with the benzodiazepine antagonist, flumazenil(Drug information on flumazenil). However, the combination of a benzodiazepine and alcohol can be lethal.

Rebound
Discontinuation of many hypnotics is often followed by worsening of sleep disruptions relative to pretreatment levels. In practical terms, patients with insomnia find that their sleep is disturbed for a night or 2 after abrupt discontinuation of what appeared to be effective medication. The risk of rebound is greater with drugs that have a short half-life than with those that have a longer half-life. Tapering lessens the likelihood of rebound. However, there is little evidence that rebound insomnia leads to the resumption of medication.14

Dependence
Dependence may supervene on the longer-term use of hypnotics; giving a long-acting benzodiazepine drug only once in 24 hours does not protect against such an eventuality. Because of such concerns, hypnotics are usually prescribed for no more than 2 to 4 weeks. Tapering manages the withdrawal syndrome.

A growing problem with these drugs is abuse—nonmedical use, on a regular or sporadic basis, often in a polydrug context. The injected drug has a marked sedative and/or disinhibiting effect, and its use may result in chaotic behavior.

Clinical use
Insomnia is common, especially in the elderly.15,16 In patients who complain of severe insomnia secondary to physical concerns—pain, breathlessness, or pruritus—the primary symptoms are treated first. In other cases, the insomnia may be either a symptom of psychiatric distress, anxiety, or depression, or it may be iatrogenic, caused by the very drugs prescribed to relieve it. In this instance, a careful regimen of drug withdrawal, or substitution and subsequent withdrawal, should be initiated.

Pages: 1  2  3  
Previous Next
 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.

Also in this Special Report

Introduction: The Art of Psychopharmacology

Hypnotics

Antidepressants: Brand Name or Generic?






 
TOPIC INDEX

Addiction Medicine
Alzheimer Disease
Anxiety Disorders
ADHD
Bipolar Disorder
Child & Adolescent Psychiatry
Dementia
Depression
DSM-5
Geriatric Psychiatry

 

Health Care Reform
Major Depressive
Disorder
OCD
Personality Disorders
Schizoaffective Disorder
Schizophrenia
Sleep Disorders
Somatoform Disorders
All Topics

 


 
FROM PHYSICIANS PRACTICE
Five Steps to Improving Patient Access
Judy Capko,  May 21, 2013
Patient access is getting increased attention through reform initiatives. Here are five steps you can take to make sure patients get appropriate access to care in your office.
Growing HIPAA Threat – Ignore Windows XP at Your Own Peril
Marion K. Jenkins,  May 21, 2013
Chances are good that you have some major ticking software time bombs lurking in your medical practice's computer environment, namely Windows XP and Server 2003.
Finding Physician Work-Life Balance in the Small Moments
Jennifer Frank, MD,  May 21, 2013
At my practice and at home, things are always busy. There's laundry or homework, or a patient with needs.
Three Areas to Reduce Costs at Your Medical Practice
Greg Mertz,  May 19, 2013
By taking a hard look at reducing costs for staffing, overhead, and technology at your medical practice, you may see increased physician compensation.
Dos and Don’ts for Starting a Physician Blog
Michael Woo-Ming, MD,  May 18, 2013
Starting a physician blog can provide your medical practice with marketing benefits, but it's important to do it right.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Developmental Psychopathology Comes of Age
  • The Moral Struggles of Practicing Psychiatrists
  • Grief and Depression: The Sages Knew the Difference
  • Update on Mental Health Benefits and Substance Use Disorder Services Under the Affordable Care Act
  • Synthetic Cathinones: Signs, Symptoms, and Treatment
  • Grief and Depression: The Sages Knew the Difference
  • Successful Aging: Strategies to Help Maintain and Nurture a Healthy Brain
  • Synthetic Cathinones: Signs, Symptoms, and Treatment
  • Developmental Psychopathology Comes of Age
  • Psychiatry and the Myth of “Medicalization”
  • Experts Discuss Changes, Updates in DSM-5
  • The Paradox of Choice: When More Medications Mean Less Treatment
  • Will Your Clinical Records Support You in Court?
  • Refinements in ECT Techniques
  • Successful Aging: Strategies to Help Maintain and Nurture a Healthy Brain
Click here to subscribe to our newsletter
 
COMMENTS
  • Most Commented
  • Most Recent
  • Grief and Depression: The Sages Knew the Difference
  • Psychiatry and the Myth of “Medicalization”
  • Is it Time for a Treatment Manual to Complement DSM-5?
  • NIMH vs DSM 5: No One Wins, Patients Lose
  • DSM-5 Won’t Solve the Overdiagnosis Problem—But Clinicians Can
  • The Paradox of Choice: When More Medications Mean Less Treatment
  • Experts Discuss Changes, Updates in DSM-5
  • New Insight Into the Neurobiology of Depression
  • Tie One On for Patients
  • NIMH vs DSM 5: No One Wins, Patients Lose
Click here to subscribe to our newsletter
 
CAREER CENTER

  •   Featured Jobs  
  •    Resources   
  • Psychiatry and Nurse Practitioner Opportunities
  • Associate Medical Director - Psychiatrist Delray Beach, Florida
  • Retiring Child Psychiatrist Seeks Replacement August 2010 or Before
  • Chairperson, Dept of Psychiatry Needed
  • FT Staff Psychiatrist - Excellent Benefits
  • BC Adult and Child Psychiatrits - PT and FT Positions Available
  • Managing Risks When Practicing in Three-Party Care Settings
  • 12 Tips for Making Your Practice Greener
  • Keys to Avoiding Malpractice: Standard of Care in Psychiatric Practice
  • Take This Job and Shove It
  • Merging Administrative and Academic Careers in Psychiatry
 
SearchMedica SEARCH RESULT

Find peer-reviewed literature and websites for practicing medical professionals

CME on Display
Evidence on Display
Guidelines on Display
Patient Education on Display
Clinical Trials on Display
Practical Articles on Display
Research and Reviews on Display
All "Display" results

CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy